TrialWorld journal of urology2025

Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial.

Xuyu Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.